Sparx Group Announces First Patient Dosed With SPX-303 Injection, the First in Its Class of Anti-Lilrb2/Pd-L1 Bispecific Antibody Drugs
Sparx 集團宣佈首位患者接種 SPX-303 注射劑,這是同類抗Lilrb2/Pd-L1 雙特異性抗體藥物中的第一種
Sparx Group Announces First Patient Dosed With SPX-303 Injection, the First in Its Class of Anti-Lilrb2/Pd-L1 Bispecific Antibody Drugs
Sparx 集團宣佈首位患者接種 SPX-303 注射劑,這是同類抗Lilrb2/Pd-L1 雙特異性抗體藥物中的第一種
譯文內容由第三人軟體翻譯。